Next Article in Journal
Anti-Diabetic Effect of Organo-Chalcogen (Sulfur and Selenium) Zinc Complexes with Hydroxy-Pyrone Derivatives on Leptin-Deficient Type 2 Diabetes Model ob/ob Mice
Next Article in Special Issue
Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents
Previous Article in Journal
Poly-γ-glutamic Acid Synthesis, Gene Regulation, Phylogenetic Relationships, and Role in Fermentation
Previous Article in Special Issue
Clinical Usefulness of the Platelet-to Lymphocyte Ratio in Patients with Angiosarcoma of the Face and Scalp
Open AccessArticle

CMG2 Expression Is an Independent Prognostic Factor for Soft Tissue Sarcoma Patients

1
Center for Reproductive Medicine and Andrology, Martin Luther University, 06120 Halle (Saale), Germany
2
Department of Oral and Maxillofacial Plastic Surgery, Martin Luther University Halle-Wittenberg, 06120 Halle (Saale), Germany
3
Department of Radiotherapy, Martin Luther University Halle-Wittenberg, 06120 Halle (Saale), Germany
4
Institute of Medical Microbiology, Martin Luther University Halle-Wittenberg, 06120 Halle (Saale), Germany
5
Institute of Pathology, Martin Luther University Halle-Wittenberg, 06120 Halle (Saale), Germany
6
Department of General and Visceral Surgery, Hospital Dessau, 06847 Dessau-Roßlau, Germany
7
Clinic of Urology, FA University Hospital Erlangen-Nuremberg, 91054 Erlangen, Germany
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2017, 18(12), 2648; https://doi.org/10.3390/ijms18122648
Received: 6 November 2017 / Revised: 29 November 2017 / Accepted: 30 November 2017 / Published: 7 December 2017
(This article belongs to the Special Issue Current Advances in Soft Tissue and Bone Sarcoma)
The capillary morphogenesis gene 2 (CMG2), also known as the anthrax toxin receptor 2 (ANTXR2), is a transmembrane protein putatively involved in extracellular matrix (ECM) adhesion and tissue remodeling. CMG2 promotes endothelial cell proliferation and exhibits angiogenic properties. Its downregulation is associated with a worsened survival of breast carcinoma patients. Aim of this study was to analyze the CMG2 mRNA and protein expression in soft tissue sarcoma and their association with patient outcome. CMG2 mRNA was measured in 121 tumor samples of soft tissue sarcoma patients using quantitative real-time PCR. CMG2 protein was evaluated in 52 tumor samples by ELISA. CMG2 mRNA was significantly correlated with the corresponding CMG2 protein expression (rs = 0.31; p = 0.027). CMG2 mRNA expression was associated with the mRNA expressions of several ECM and tissue remodeling enzymes, among them CD26 and components of the uPA system. Low CMG2 mRNA expression was correlated with a worsened patients’ disease-specific survival in Kaplan-Meier analyses (mean patient survival was 25 vs. 96 months; p = 0.013), especially in high-stage tumors. A decreased CMG2 expression is a negative prognostic factor for soft tissue sarcoma patients. CMG2 may be an interesting candidate gene for the further exploration of soft tissue sarcoma genesis and progression. View Full-Text
Keywords: CMG2; soft tissue sarcoma; pathobiology; outcome CMG2; soft tissue sarcoma; pathobiology; outcome
Show Figures

Graphical abstract

MDPI and ACS Style

Greither, T.; Wedler, A.; Rot, S.; Keßler, J.; Kehlen, A.; Holzhausen, H.-J.; Bache, M.; Würl, P.; Taubert, H.; Kappler, M. CMG2 Expression Is an Independent Prognostic Factor for Soft Tissue Sarcoma Patients. Int. J. Mol. Sci. 2017, 18, 2648.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop